First Do No Harm? Modeling Risks and Benefits of Challenge Trials for Hepatitis C Vaccine Development.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）
摘要
Benefits of a challenge approach increase with more vaccine candidates, faster challenge trials, and greater uptake.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要